Přehled o publikaci
2025
Patterns of SARS-CoV-2-specific humoral and cellular immune response in actively treated patients with solid cancer following prime BNT162b2 COVID-19 vaccination: results from phase IV CoVigi trial
LORDICK OBERMANNOVÁ, Radka; Iveta SELINGEROVÁ; Regina DEMLOVÁ; Dominika OKRUHLICOVÁ; Jiří NEVRLKA et. al.Basic information
Original name
Patterns of SARS-CoV-2-specific humoral and cellular immune response in actively treated patients with solid cancer following prime BNT162b2 COVID-19 vaccination: results from phase IV CoVigi trial
Authors
LORDICK OBERMANNOVÁ, Radka; Iveta SELINGEROVÁ; Regina DEMLOVÁ; Dominika OKRUHLICOVÁ; Jiří NEVRLKA; Kateřina ČERNÁ PILÁTOVÁ; Kristina GREPLOVA; Zdenka CERMAKOVA; Dalibor VALÍK; Igor KISS; Marketa PALACOVA; Alexandr POPRACH; Hana LEJDAROVA; Sarka SELVEKEROVA; Martina VANECKOVA and Lenka ZDRAŽILOVÁ DUBSKÁ
Edition
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, LONDON, SAGE PUBLICATIONS LTD, 2025, 1758-8340
Other information
Language
English
Type of outcome
Article in a journal
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
is not subject to a state or trade secret
References:
Organization
Lékařská fakulta – Repository – Repository
UT WoS
001489582200001
EID Scopus
2-s2.0-105005423791
Keywords in English
COVID-19 vaccination; immune response; SARS-CoV-2 antibodies; SARS-CoV-2-specific T-cell response; solid cancer
Links
CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód Repo. LX22NPO5102, research and development project. 101059788, interní kód Repo. CZECRIN IV, large research infrastructures.
Changed: 15/10/2025 00:50, RNDr. Daniel Jakubík
Abstract
In the original language
amp; iuml;ve patients with cancer developed anti-S antibodies after the first vaccine dose, rising to 92% after the second dose. By 6 months, all BNT162b2-vaccinated patients with solid cancer developed antibody response. Patients treated with CT showed impaired both humoral and cellular immune response to BNT162b2 vaccination. Antibody levels in SARS-CoV-2-recovered patients were comparable to healthy controls. T-cell response peaked after the second dose of BNT162b2 and was not significantly impaired in solid cancer patients except those treated with CT.Conclusion: Immune response to BNT162b2 COVID-19 mRNA vaccine is substantially shaped by pre-vaccination COVID-19 infection. All patients with solid cancer on active anticancer therapy exhibited seroconversion after COVID-19 vaccination, although the extent of both humoral and cell immune response was substantially hampered in those treated by CT.Trial registration: EudraCT No. 2021-000566-14 (registration date February 17, 2021).
